Fast Track to Market – Possible Pathways for FDA Approval or Authorization During COVID-19

As part of the global fight against coronavirus (COVID-19), FDA is working closely with medical product sponsors and investigators to find a potential treatment. As part of these efforts, multiple FDA expedited pathways may be available to the medical product industry and healthcare providers for the study and use of COVID-19 treatments. Join us for a presentation discussing those pathways.

TOPICS WILL INCLUDE:

• Expanded access (compassionate use)
• Right-to-try
• Emergency use authorization
• Coronavirus Treatment Acceleration Program (CTAP)
• Related FDA guidance documents